Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40JGP | ISIN: US51817R2058 | Ticker-Symbol: LFL0
Tradegate
04.11.24
13:10 Uhr
24,200 Euro
-0,600
-2,42 %
1-Jahres-Chart
LATAM AIRLINES GROUP SA ADR Chart 1 Jahr
5-Tage-Chart
LATAM AIRLINES GROUP SA ADR 5-Tage-Chart
RealtimeGeldBriefZeit
24,40025,40021:56
24,80025,00021:55
GlobeNewswire (Europe)
632 Leser
Artikel bewerten:
(2)

LATAM Airlines Group S.A. Announces Updates on its Process to Re-Opening and Relisting of its ADR Program

Santiago, Chile, July 18, 2024 - As part of its advances in the process to re-open and relist its ADR program, LATAM Airlines Group S.A. (the "Company" or "LATAM"), announced plans to change the ratio of its American Depositary Shares ("ADSs") to its common shares from one (1) ADS, representing one (1) common share, to one (1) ADS representing two thousand (2,000) common shares (the "Ratio Change"). The Ratio Change is expected to become effective on or about July 24, 2024 (the "Effective Date").

For the holders of the Company's American Depositary Receipts representing ADSs (the "ADRs"), the Ratio Change has the same effect as a one-for-two-thousand reverse ADS split and will have no impact on an ADR holder's proportional equity interest in the Company. The Ratio Change is intended to result in a price per ADS in a customary range for a new exchange-listed equity security for purposes of satisfying the requirements of the New York Stock Exchange ("NYSE"). As disclosed in the Material Facts dated April 3, 2024, July 2, 2024 and July 18, 2024, the Board of Directors of the Company has approved the initiation of the process to open and relist the Company's ADRs on NYSE, and such process is currently ongoing. When the Company relists its ADRs on the NYSE, it expects they will trade under the ticker symbol "LTM."

On the Effective Date, holders of uncertificated ADRs in the Direct Registration System ("DRS") and The Depository Trust Company ("DTC") will have their ADRs automatically exchanged and need not take any action. In such a case , the exchange of every two thousand (2,000) then-held (existing) ADSs for one (1) new ADS will occur automatically at the Effective Date, with the then-held ADSs being cancelled and new ADSs being issued by the Depositary. Registered holders of certificated ADRs will be required on a mandatory basis to surrender their certificated ADRs to JPMorgan Chase Bank, N.A., the depositary bank (the "Depositary"), for cancellation and will receive one (1) new ADR representing one (1) ADS in exchange for every two thousand (2,000) existing ADSs (as represented in the surrendered ADR). ADS beneficial holders who hold through an ADR holder intermediary need not take any action in connection with the Ratio Change.

For a limited period of time, the Company has agreed to assume the following fees, if any: (i) cancellation fees from the date of this announcement to the Effective Date; (ii) in connection with the first registered offering of our securities following the date hereof, issuance or cancellation fees during the ten (10) business days after the pricing date; and (iii) issuance fees for all ADRs issued in connection with follow-on offerings registered with the SEC in excess of U.S.$50 million, and cancellation fees for all ADRs cancelled in the five (5) business days after the settlement date of such follow-on offerings.

No fractional new ADSs will be issued in connection with the Ratio Change. Instead, fractional entitlements to new ADSs will be aggregated and sold, and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes, and expenses) will be distributed to the applicable ADR holders by the Depositary.

Any ADS holder that, as a consequence of the Ratio Change, would receive a fractional entitlement to an ADS as described above, may be entitled to withdraw its common shares underlying the ADS from the Depositary's facility at no cost to such holder prior to the Effective Date by contacting the Depositary.

The Company's total outstanding stock amounts to approximately 604 billion common shares, which on an ADS adjusted basis would amount to approximately 302 million ADSs, considering the Ratio Change. The Company's Board of Directors also approved on July 17, 2024 the registration of an additional 100,000,000 ADSs to be added to the 217,000,000 ADSs currently registered, totaling approximately 317,000,000 ADSs registered. These new ADSs will be available for all future issuances of ADSs, including to those shareholders who, from time to time, opt to exchange their shares for ADSs in our ADR program.
© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.